Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

334
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
334
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

2.3K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

131
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
131
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

384
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
384

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent Network Localization of Brain Stimulation Targets for Trait Anxiety.

The American journal of psychiatry·2026
Same author

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Nature medicine·2026
Same author

Definitive Radiation Therapy for Older Adults With Localized Prostate Cancer.

Cureus·2026
Same author

Altered neurodevelopmental trajectories of brain structure in Tourette syndrome and Chronic Tic Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

Developmental delay in attaining adult levels of motor excitability in children and adolescents with Tourette syndrome: a mega-analysis study.

bioRxiv : the preprint server for biology·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

Related Experiment Video

Updated: Mar 27, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K

The Human Experience with Intravenous Levodopa.

Shan H Siddiqi1, Natalia K Abraham2, Christopher L Geiger3

  • 1Department of Psychiatry, Washington University School of Medicine St. Louis, MO, USA.

Frontiers in Pharmacology
|January 19, 2016
PubMed
Summary
This summary is machine-generated.

Intravenous levodopa (IV levodopa) has been safely administered to over 2760 individuals, demonstrating a comparable safety profile to oral levodopa. This review compiles human experience for regulatory review.

Keywords:
DOPAFDAINDParkinsoncarbidopaintravenouslevodopapharmacokinetics

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Related Experiment Videos

Last Updated: Mar 27, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Research

Background:

  • Intravenous (IV) levodopa use is documented for over 50 years.
  • Regulatory agencies require comprehensive toxicity data for non-FDA-approved drug administration routes.
  • Investigational New Drug (IND) applications necessitate detailed reviews of alternate route safety.

Purpose of the Study:

  • To compile human experience data for intravenous levodopa.
  • To provide information required by regulatory agencies for IV levodopa.
  • To summarize safety and efficacy of IV levodopa.

Main Methods:

  • Systematic review of over 200 articles on IV levodopa.
  • Examination of administration details, pharmacokinetics, benefits, and side effects.
  • Analysis of 142 original reports on human IV levodopa use.

Main Results:

  • At least 2760 subjects received IV levodopa since 1959.
  • Outcomes studied include parkinsonian signs, sleep, hormones, hemodynamics, and cognition.
  • Side effects were consistent with oral levodopa; no deaths or psychosis reported.

Conclusions:

  • Intravenous levodopa has been administered to at least 2760 patients.
  • The safety profile of IV levodopa is comparable to oral administration.
  • Human experience data supports the safety of IV levodopa.